Stanley Laman Group Ltd. Takes $3.68 Million Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Stanley Laman Group Ltd. acquired a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, Holdings Channel reports. The fund acquired 59,404 shares of the medical equipment provider’s stock, valued at approximately $3,683,000.

A number of other institutional investors have also recently bought and sold shares of the company. Tucker Asset Management LLC boosted its stake in Lantheus by 239.0% in the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares during the period. First Horizon Advisors Inc. boosted its position in shares of Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 225 shares during the period. Covestor Ltd grew its holdings in shares of Lantheus by 62.7% during the third quarter. Covestor Ltd now owns 527 shares of the medical equipment provider’s stock worth $37,000 after buying an additional 203 shares in the last quarter. Parkside Financial Bank & Trust raised its position in Lantheus by 36.6% in the 3rd quarter. Parkside Financial Bank & Trust now owns 582 shares of the medical equipment provider’s stock valued at $40,000 after buying an additional 156 shares during the last quarter. Finally, NBC Securities Inc. bought a new stake in Lantheus in the 3rd quarter valued at approximately $46,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Insider Buying and Selling at Lantheus

In other Lantheus news, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the business’s stock in a transaction dated Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, Director Mary Anne Heino sold 93,863 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $65.31, for a total value of $6,130,192.53. Following the transaction, the director now owns 251,643 shares in the company, valued at approximately $16,434,804.33. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the stock in a transaction on Wednesday, March 6th. The stock was bought at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the acquisition, the insider now owns 116,773,394 shares in the company, valued at $110,934,724.30. The disclosure for this purchase can be found here. Insiders have sold 94,545 shares of company stock worth $6,169,936 over the last 90 days. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Down 0.0 %

LNTH traded down $0.01 during trading on Thursday, reaching $65.20. 602,999 shares of the stock were exchanged, compared to its average volume of 1,036,479. The stock has a market cap of $4.47 billion, a P/E ratio of 14.05 and a beta of 0.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The stock’s 50 day moving average price is $61.31 and its two-hundred day moving average price is $62.75. Lantheus Holdings, Inc. has a twelve month low of $50.20 and a twelve month high of $100.85.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The company had revenue of $354.00 million for the quarter, compared to analyst estimates of $350.44 million. Equities analysts expect that Lantheus Holdings, Inc. will post 5.96 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. B. Riley raised their price target on shares of Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. JMP Securities restated a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research note on Saturday, January 13th. Finally, Truist Financial restated a “buy” rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a research note on Monday, February 26th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and an average price target of $104.71.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.